Zacks Research Has Negative Estimate for PCRX Q4 Earnings

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Equities researchers at Zacks Research reduced their Q4 2026 EPS estimates for Pacira BioSciences in a research note issued on Thursday, July 17th. Zacks Research analyst R. Department now anticipates that the company will earn $0.65 per share for the quarter, down from their previous forecast of $0.66. The consensus estimate for Pacira BioSciences’ current full-year earnings is $2.41 per share. Zacks Research also issued estimates for Pacira BioSciences’ Q2 2027 earnings at $0.61 EPS.

Other equities analysts have also issued research reports about the stock. HC Wainwright increased their target price on shares of Pacira BioSciences from $48.00 to $65.00 and gave the stock a “buy” rating in a research report on Tuesday, April 8th. Needham & Company LLC cut their price objective on shares of Pacira BioSciences from $32.00 to $30.00 and set a “buy” rating for the company in a research report on Friday, May 9th. Finally, Wall Street Zen upgraded shares of Pacira BioSciences from a “hold” rating to a “buy” rating in a research report on Friday, June 6th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, Pacira BioSciences currently has an average rating of “Hold” and an average target price of $26.44.

Pacira BioSciences Price Performance

Shares of NASDAQ:PCRX opened at $21.59 on Monday. The company has a quick ratio of 1.99, a current ratio of 2.41 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $999.40 million, a PE ratio of -9.47 and a beta of 0.48. Pacira BioSciences has a twelve month low of $11.16 and a twelve month high of $27.64. The company has a 50-day moving average price of $24.54 and a two-hundred day moving average price of $24.44.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in PCRX. Charles Schwab Investment Management Inc. increased its stake in shares of Pacira BioSciences by 16.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 502,204 shares of the company’s stock worth $9,462,000 after buying an additional 70,307 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Pacira BioSciences in the fourth quarter worth $190,000. PNC Financial Services Group Inc. increased its stake in shares of Pacira BioSciences by 16.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock worth $68,000 after buying an additional 513 shares during the period. Teacher Retirement System of Texas increased its stake in shares of Pacira BioSciences by 17.4% in the fourth quarter. Teacher Retirement System of Texas now owns 13,708 shares of the company’s stock worth $258,000 after buying an additional 2,034 shares during the period. Finally, American Century Companies Inc. increased its stake in shares of Pacira BioSciences by 46.6% in the fourth quarter. American Century Companies Inc. now owns 135,592 shares of the company’s stock worth $2,555,000 after buying an additional 43,123 shares during the period. 99.73% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Pacira BioSciences

In other Pacira BioSciences news, SVP Lauren Riker sold 5,578 shares of Pacira BioSciences stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $26.21, for a total transaction of $146,199.38. Following the transaction, the senior vice president directly owned 59,564 shares of the company’s stock, valued at approximately $1,561,172.44. This trade represents a 8.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 6.40% of the company’s stock.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.